For diarrhea, maintaining hydration and considering temporary dietary adjustments may help
Antisense Oligonucleotides Targeting Apolipoprotein(a) in People with Raised Lipoprotein(a): Two Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Trials. Lancet (London, England), vol
Any weight loss after a plateau represents a genuine breakthrough
This triple agonist design, developed by Eli Lilly under the research code LY3437943, represents a fundamentally different approach from semaglutide (which targets only GLP-1) or tirzepatide (which targets GLP-1 and GIP)
Communication with your healthcare team about symptom severity and impact on daily functioning is essential for optimizing your treatment plan
Supports the bodys natural metabolic signaling pathways associated with satiety and metabolic function